ARID1A and neoplasm: Targeted cancer gene panel sequencing of the primary tumor specimens identified a few additional mutations, including one patient each with pathogenic germline mutations in APC and ARID1A, while the remaining mutations were variants of unknown significance (Supplementary Table S3).